Scandinavian ChemoTech

The order is placed by Pompano Veterinary Oncology (PVO) in Boca Raton, Florida. PVO offers full-service, high-quality cancer treatment options for companion animals, with the goal of advancing the fight against cancer. This veterinary hospital is equipped with state of the art and leading technology for diagnostics and treatment. PVO perform treatments both at their hospital and through their "mobile cancer unit". The portability and adaptability of vetIQure™, coupled with its gentle TSE treatment, prove valuable within PVO's comprehensive strategy.

"At PVO it is our goal to be at the vanguard of cancer treatment for companion animals. We want to provide progressive and innovative treatments to improve our patient's quality of life while minimizing stress and adverse effects.  TSE provides a key weapon in our arsenal against cancer in companion animals that we have been looking for.  It allows us to target tumors effectively  while  sparing  healthy  normal  tissues  of  undesired  damage.  As  a  veterinary oncologist, I appreciate the compact size, "easy to use" feel and portability of vetIQure.  With vetIQure, we can provide additional, effective, and safe treatments in our mobile oncology unit "at home", which is much desired by pet owners." – says Dr Pedro A. Dominguez, DVM at Pompano Veterinary Oncology.

For further information please contact:

Mohan Frick, CEO
Phone: +46 (0)10-218 93 00
E-mail: ir@chemotech.se

This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 15 December 2023 14:30 CET.

Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.